Related Experiment Video
Updated: Feb 8, 2026

Isolation and Analysis of Aortic Arch and Root Lesions in an Atherosclerotic Mouse Model
Published on: February 14, 2025
Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation
Shinobu Miyazaki-Anzai1, Masashi Masuda1, Shohei Kohno1
1Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Denver, Aurora, CO 80045.
Abstract:
Simultaneous activation of bile acid receptors farnesoid X receptor (FXR) and G protein-coupled bile acid receptor 1 (TGR5) by INT-767 significantly reduces atherosclerotic formation. In this study, we investigated the effect of simultaneous inactivation of these bile acid receptors in atherosclerosis and which bile acid receptor mediates the anti-atherogenic effect of INT-767. To investigate the role of simultaneous inactivation of FXR and TGR5 in vivo, we generated LDL receptor knockout (LDLR) KO mice with FXR and TGR5 dual deficiency, which exhibited severe atherosclerosis and aortic inflammation through nuclear factor κΒ activation. The lipid-lowering effects of INT-767 were completely blocked by FXR single deficiency but not TGR5 single deficiency. INT-767 was able to block atherosclerotic formation and decrease levels of aortic cytokines and chemokines in LDLR KO mice under either FXR or TGR5 single deficiency. Dual deficiency of FXR and TGR5 completely blocked the anti-atherogenic and anti-inflammatory effects of INT-767 in LDLR KO mice. We demonstrated that 1) FXR and TGR5 dual deficiency exacerbated the development of atherosclerosis and 2) the anti-atherogenic effect of INT-767 requires the anti-inflammatory effect but not the lipid-lowering effect through the simultaneous activation of FXR and TGR5. Our results indicate that dual activation of FXR and TGR5 is a promising strategy for treating atherosclerosis.
Insights
Simultaneously activating farnesoid X receptor (FXR) and TGR5 reduces atherosclerosis. Blocking both receptors worsens disease, indicating dual activation is key for INT-767
Area of Science:
- Cardiovascular Research
- Metabolic Diseases
- Pharmacology
Background:
- Atherosclerosis involves lipid accumulation and inflammation in arteries.
- Bile acid receptors, farnesoid X receptor (FXR) and TGR5, are implicated in metabolic regulation.
- Simultaneous activation of FXR and TGR5 by INT-767 shows promise in reducing atherosclerosis.
Purpose of the Study:
- To investigate the impact of simultaneously inactivating FXR and TGR5 on atherosclerosis.
- To determine which bile acid receptor mediates the anti-atherogenic effects of INT-767.
Main Methods:
- Generated LDL receptor knockout (LDLR KO) mice with dual FXR and TGR5 deficiency.
- Administered INT-767 to assess its effects on atherosclerosis, lipid levels, and aortic inflammation.
- Analyzed nuclear factor κB activation and cytokine/chemokine levels.
Main Results:
- Dual deficiency of FXR and TGR5 exacerbated atherosclerosis and aortic inflammation.
- INT-767's lipid-lowering effect was blocked by FXR deficiency alone.
- INT-767's anti-atherogenic and anti-inflammatory effects were abolished by dual FXR and TGR5 deficiency.
Conclusions:
- Dual activation of FXR and TGR5 is crucial for INT-767's anti-atherogenic and anti-inflammatory actions.
- The anti-atherogenic effect of INT-767 relies on its anti-inflammatory, not lipid-lowering, properties via dual receptor activation.
- Simultaneous FXR and TGR5 activation represents a promising therapeutic strategy for atherosclerosis.
Related Concept Videos
Feedback Inhibition
Enzyme Inhibition
Inhibition of Cdk Activity
Formation of Species
Solution Formation
This selective...
Standard Enthalpy of Formation

